Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
9.80
+0.43 (4.59%)
At close: Feb 20, 2026, 4:00 PM EST
9.99
+0.19 (1.94%)
After-hours: Feb 20, 2026, 7:41 PM EST
Lipocine Revenue
Lipocine had revenue of $114.57K in the quarter ending September 30, 2025. In the year 2024, Lipocine had annual revenue of $11.20M with 264.67% growth.
Revenue (ttm)
$11.20M
Revenue Growth
+264.67%
P/S Ratio
12.59
Revenue / Employee
$270,168
Employees
16
Market Cap
54.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.20M | 8.13M | 264.67% |
| Dec 31, 2023 | 3.07M | 2.57M | 514.16% |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 164.99K | -263.04K | -61.45% |
| Dec 31, 2018 | 428.03K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 7.71M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 30.91M |
| TScan Therapeutics | 8.42M |
| Radiopharm Theranostics | 8.20M |
| Nutriband | 2.28M |
| BeyondSpring | 1.88M |
| Spruce Biosciences | 697.00K |
LPCN News
- 4 days ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 4 weeks ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 5 weeks ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PRNewsWire
- 3 months ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 3 months ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire
- 5 months ago - Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PRNewsWire